Aurinia Pharma Inc Live Stock Price Today, Share Analysis and Chart

Name: Aurinia Pharmaceuticals Inc: Is Infosys Ltd. worth buying?
Item: Aurinia Pharmaceuticals Inc
Rating: 2.28420825
Author: Trendlyne DVM scores

Risky Value

about

Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for ...

14.80 0.43 (2.99%)

117.01% Gain from 52W Low

857.1K

XNAS Volume

XNAS 10 Mar, 2026 5:30 PM (EDT)

Low Financial Strength

33.3 / 100

Affordable Valuation

58.0 / 100

Technically Neutral

58.1 / 100

Risky Value These stocks have weak financials and average momentum. They may be affordable, but investors should exercise caution View Similar Embed DVM

1Yr Price target upside is 15%

7 analysts

Aurinia Pharma Inc Live Price Chart

Switch to TradingView

Loading Fundamental data..

Loading data..

Aurinia Pharma Inc Live Stock Price Today, Share Analysis and Chart

Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for ...

117.01% Gain from 52W Low

SWOT Analysis

Aurinia Pharma Inc Live Price Chart